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Abstract. To protect the body efficiently from infec- 
tious organisms, leukocytes circulate as nonadherent 
cells in the blood and lymph, and migrate as adherent 
cells into tissues. Circulating leukocytes in the blood 
have first to adhere to and then to cross the endothelial 
lining. CD31/PECAM-1 is an adhesion molecule ex- 
pressed by vascular endothelial cells, platelets, mono- 
cytes, neutrophils, and naive T lymphocytes. It is a 
transmembrane glycoprotein of the immunoglobulin 
gene superfamily (IgSF), with six Ig-like homology 
units mediating leukocyte-endothelial interactions. The 
adhesive interactions mediated by CD31 are complex 
and include homophilic (CD31-CD31) or heterophilic 
(CD31-X) contacts. Soluble, recombinant forms of 
CD31 allowed us to study the heterophilic interactions 
in leukocyte adhesion assays. We show that the adhe- 
sion molecule otv[33  integrin is a ligand for CD31. The 
leukocytes revealed adhesion mediated by the second 
Ig-like domain of CD31, and this binding was inhibited 
by av[33 integrin-specific antibodies. Moreover Otv~  3 was 
precipitated by recombinant CD31 from cell lysates. 
These data establish a third IgSF-integrin pair of adhe- 
sion molecules, CD31-otvI33  in addition to VCAM-1, 
MadCAM-1/ot4 integrins, and ICAM/B2 integrins, 
which are major components mediating leukocyte- 
endothelial adhesion. Identification of a further versa- 
tile adhesion pair broadens our current understanding 
of leukocyte-endothelial interactions and may provide 
the basis for the treatment of inflammatory disorders 
and metastasis formation. 
I 
NTEGRINS are members of a large family of adhesion 
receptors, composed of two noncovalently associated 
chains, the ot and the 13 chain. They play a central role 
in cell adhesion and migration. Integrins function in both, 
cell--cell and  cell-substratum adhesion.  Different combi- 
nations of ct and 13 subunits give rise to receptors with dif- 
ferent ligand specificities. The et chain carries three to four 
divalent cation-binding sites making the functioning of in- 
tegrins crucially dependent on these cations (23, 33, 34, 44, 
75). The integrin av133 is expressed by several cell types in- 
cluding endothelial cells  (14), dendritic epidermal T cells 
(38, 46), activated T cells  (49, 58, 71), B  lymphoblastoid 
cell lines  (61),  mast cells (7, 83), NK cells (57),  and lym- 
phokine-activated killer (LAK)  1 cells (56, 72). It is a celhi- 
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ICAM,  intercellular  adhesion  molecule;  IgSF,  immunoglobulin  gene 
superfamily;  IL-2,  Interleukin-2;  LAK,  lymphokine-activated  killer; 
PECAM, platelet endothelial cell adhesion molecule; VCAM, vascular 
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lar receptor for the extraceUular matrix molecules (ECM) 
vitronectin, fibronectin, laminin,  thrombospondin, osteo- 
pontin, bone sialoprotein, and denatured collagen type I 
and  also recognizes products of the coagulation-cascade 
like fibrinogen and yon Willebrand-factor.  The recogni- 
tion  epitope  on  these  molecules  is  the  amino  acid  se- 
quence Arg-Gly-Asp (i.e., RGD) (13, 25, 37, 66, 67). So far 
there is no ligand described for OLv133  which mediates cell- 
cell adhesion. 
CD31/PECAM-1 is a single  chain molecule containing 
six Ig-like  domains of the C2 subclass,  a transmembrane 
stretch and a cytoplasmic tail (52, 81). It is expressed on 
cells  of the vascular compartment and is a cell-adhesion 
molecule (CAM) implicated in many physiological events. 
These include leukocyte-endothelial interactions, transen- 
dothelial  migration,  inter-endothelial  cell  adhesion  and 
angiogenesis  (for review see 20,  21).  Cell-cell  adhesion 
mediated by CD31 can occur in both homophilic and het- 
erophilic ways. It is thought that during homophilic inter- 
actions, one CD31 molecule interdigitates with another on 
the adjacent cells  making  antiparaUel  contacts requiring 
all six domains. Active binding sites for homophilic adhe- 
sion were proposed to reside within domains 2-3 and 5-6 
(24). Loss of any one domain of CD31 completely disables 
homophilic binding due to incorrect spacing.  Heterophilic 
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second Ig-like domain which contains a  heparin-binding 
consensus sequence. The heterophilic binding is perturbed 
by sulfated glycosaminoglycans (GAGs) and is completely 
dependent on divalent cations (19, 22, 50). However, there 
is no direct evidence that cells indeed interact with each 
other via GAG-CD31, and the divalent cation dependency 
has remained  unexplained.  Identification of the hetero- 
philic ligand for CD31 would lead to a better understand- 
ing of the function of CD31 and its involvement in physio- 
logical and pathological events. 
Materials and Methods 
Animals and Cell Lines 
For this study, all cell lines and reagents are of murine origin or directed 
against antigens of routine origin, except where otherwise stated. 10-20- 
wk-old, male or female C57BL/6, DBA-2, Balb-c, and Lewis mice were 
used. 10-wk-old C.B-17 severe combined immunodeficient (SCID) mice 
were from Iffa-Credo, L'Arbresle, France. For the generation of poly- 
clonal antibodies, a female 3-month-old New Zealand white rabbit was 
used. Animal handling and euthanasia was performed according to local 
regulations. 
Lymphokine-activated killer (LAK) cells were prepared as described 
elsewhere (29).  Briefly, splenocytes were resuspended in 50  ml RPMI 
1640  medium (Gibco, Paisley, Scotland)  supplemented with  10%  FCS 
(Boehringer Mannheim, Germany), nonessential amino acids, 1 mM so- 
dium pyruvate, 100 U/ml penicillin, 100 izg/ml streptomycin (all GIBCO) 
and 5 ×  10 -5 M 2-ME (Fluka, Buchs, Switzerland) (hereafter referred to 
as complete medium) and  1,000  IU/ml of Interleukin-2  (IL°2)  derived 
from supernatants of IL-2 producing X63/0 BCMG Neo cells (36),  After 
3 d of incubation the adherent cells were washed twice with prewarmed 
(37°C) medium and cultured for an additional 2 d. They were harvested 
with 0.02% EDTA in PBS, washed, and resuspended with the appropriate 
buffer before use. The pro-T cell line FTF1.26 (a generous gift from Dr. R. 
Palacios, MD Anderson Cancer Center, Houston, TX) was grown as de- 
scribed (55).  Briefly, the cells were cultured in DME  medium supple- 
mented with 10%  FCS (Sera-lab, Sussex, UK), 100 U/ml penicillin, 100 
~xg/ml streptomycin and 10 IU/ml of IL-2. The ceils were harvested and 
used as LAK cells at day three after passage. Both LAK and FTF1.26 cells 
express CD31 on the surface (56 and data not shown). The myeloma cell- 
line J558L was from American Type Culture Collection (ATCC) (Rock- 
ville, MD) and was maintained in DME medium supplemented with 10% 
FCS (Sera-lab). The endothelioma cell line eEnd.2 was a generous gift of 
Dr.  W. Risau, Max-Planck Institute for Physiological and Clinical Re- 
search (Bad Nauheim, Germany). 
Reagents and Antibodies 
Polyclonal antibodies were generated by standard methods in rabbits (15). 
Briefly,  purified  CD31-6D  (see  below)  was  resuspended in  complete 
Freund's adjuvant (Difco Laboratories, Detroit, MI) by sonication. The 
antigen was injected into multiple subcutaneous sites. Booster immuniza- 
tions with incomplete Freund's adjuvant (Difco) were started 4 wk after 
the priming immunization, which was repeated twice after two subsequent 
weeks. Before the priming and after each immunization the animal was 
bled and serum prepared from whole blood. The polyclonal Abs were at 
2.2 mg/ml IgG (antiCD31) and 6.3 mg/ml IgG (anti-c~v133) and binding to 
their  respective antigens was  saturating  at  a  dilution  of 1:3,000  (anti 
CD31)  and  1:300  (anti-av133)  as  determined by FACS  ® analysis  (not 
shown). For  blocking experiments, only affinity-purified, preservative- 
free mAbs were used. The following antibodies were used: anti-av integrin 
(H9.2B8)  (46)  and  anti-133 integrin  (Hm[33)  (Pharrningen, San  Diego, 
CA); anti-aL integrin  (FD441.8)  (63)  and  anti-a  4 integrin  (PS/2)  (48) 
(ATCC); anti-131 integrin (9EG7) (given by Dr. Dietmar Vestweber, Max 
Planck Institute for Immunobiology, Freiburg, Germany) (43), anti-av in- 
tegrin (RMV-7) (obtained from Dr. Hideo Yagita, Juntendo University, 
Tokyo,  Japan)  (72);  and  anti-heparan-sulfate proteoglycan mAb  1948 
(17)  (Chemicon, Temecula, CA). The RGDS and TKPR peptides (Cal- 
biochem, La Jolla, CA), EDTA (Fluka) and Heparin (Sigma Chem. Co., 
St. Louis, MO) were of the highest purity available. 
Immunohistochemistry 
For immunohistochemical analysis of CD31 ligands, organs of SCID mice 
were removed, embedded, and frozen in Tissue-Tek, O.C.T. compound 
(Miles Inc., Elkart, IN). 6-p~m-thick frozen sections were prepared. Immu- 
nocytochemistry  was carried out using a standard APAAP technique (16). 
All the incubations were done at room temperature. The antibodies used 
for visualization of mouse cK were rabbit anti-mouse Ig (Dako, Glostrup, 
Denmark) followed by mouse anti-alkaline phosphatase eomplexed with 
alkaline phosphatase (Dako). For the detection of rat mAb binding, rabbit 
anti-rat Ig (Dako) followed by rat anti-alkaline phosphatase complexed 
with alkaline phosphatase (Dako) were used. The developing reagent was: 
137 mM N,N-dimethyl formamide, 0.4 mM naphtol-AS-BI-phosphate, 1.5 
mM Fast Red TR salt and 0.8 mM levamisole (all Sigma Chem. Co., St. 
Louis, MO) in Miehaelis buffer (143 mM sodium acetate and 143 mM 5,5- 
diethylbarbituric acid). The solution was mixed for 15 rain and filtered be- 
fore use. After a reaction time of 1 h, the sections were counterstained 
with Mayer's Hematoxylin (Merck, Darmstadt, Germany), embedded in 
Mowiol 4-88 (HOECHST, Frankfurt, Germany), examined under an Ax- 
iophot  microscope  (Zeiss,  Oberkochen,  Germany)  and  photographs 
printed with a color videoprinter UP-500P (Sony, Tokyo, Japan). 
Generation of Soluble Recombinant 
Adhesion Molecules 
Total RNA was isolated from the murine endothelial cell line eEnd.2 (80) 
and reverse transcribed into cDNA by standard methods (62). The prim- 
ers  used  for  the  amplification of coding regions  for  the  extracellular 
domains of adhesion molecules were:  5'-ATI~AGAGCTCACCATGC  - 
TCCTGGCTCTGGGACT-3'  (5'  primer  for CD31-3D,  CD31-6D  and 
CD31-6DA2), EMBL accession number L06039, 5'-TATACTTA CCTIT- 
CGGCqTGGGAAACAGCTCTGT-3'  (3' primer for CD31-3D), 5'-TA- 
TACTTACCTTTCTTCCATGGG  GCAAGGAAGAC-3' (3' primer for 
CD31-6D and CD31-6DA2), 5'-ATI'AGAGCTCATGCCTGTGAAGA- 
TGGTCGCGGTC-3'  (5'  primer  for  VCAM-1),  5'-TATACTTACCT- 
AGTTCTTTGACAGTCTCCCTTTC-3'  (3' primer for VCAM-1), EMBL 
accession number M84487,  5'-ATTAGAGCTCATGGCI~CAACCCGT- 
GCCAAGCC-3' (5' primer for ICAM-1) and 5'-TATACTTACCqTCG- 
AAAGT CCGGAGGCTCCTGGC-3' (3' primer for ICAM-1), EMBL ac- 
cession number X16624. The amplified products were purified and inserted 
into the pHT4 vector containing the mouse IgK constant region as a fusion 
partner (76)  and analyzed by nucleotide sequence analysis. A difference 
to the previously published mouse CD31 sequence (81) was found. Posi- 
tion #381 was found to be a G instead of an A, changing the amino acid se- 
quence from Arg  95 to Gly  95. To  exclude a  PCR artefact, two indepen- 
dently  isolated  CD31  cDNAs  were  resequenced  and  the  mutation 
confirmed. All other residues were as published (81).  The vectors were 
cloned into competent E. coli K803  cells and J558L myeloma cells were 
thereafter transfected by protoplast fusion (12).  Supernatants of trans- 
fected cell clones were screened by ELISA with goat anti-mouse cK re- 
agents (Southern Biotechnologies Asc. [SBA], Birmingham, AL). Super- 
natants were purified by affinity chromatography with goat anti-mouse 
cK Abs (SBA). The purified molecules were equilibrated with PBS and al- 
iquots frozen at -70°C until further use. The CD4-anti CD3-cK Janusin 
molecule is composed of the two first Ig-like domains of human CD4 
linked to an Fv fragment specific for the human CD3 molecule and cou- 
pled to mouse cK. This molecule was a kind gift of A. Traunecker (Basel 
Institute for Immunology, Switzerland) (74). To assess whether the solu- 
ble recombinant CD31 molecules were folded in a conformation compara- 
ble to native CD31, ELISA assays were performed. The rat-anti-mouse 
CD31 mAb EA-3 (56) was able to recognize the CD31-3D and CD31-6D 
but not the CD31-6DA2 molecule. Also the polyclonal Abs stained all 
three soluble recombinant CD31 isoforms and precipitate CD31 from ~25I- 
surface-labeled endothelial cells (not shown). This indicated that all three 
CD31 isoforms were folded in a manner analogous to native CD31. 
Determination of Soluble Recombinant Adhesion 
Molecules Bound to Microtiter Wells 
Approximately 20 jxg of soluble recombinant molecule was labeled with 
12si by using Iodobeads  TM (Pierce, Rockford, IL) as described in the man- 
ufacturer's instructions. Free 1251 was separated from the labeled proteins 
by size fractionation using a Sephadex G-25 column (Pharmacia, Uppsala, 
Sweden). For the assessment of the number of plate-bound molecules 0.2 
~xg/ml of radioactively labeled soluble recombinant molecule was mixed 
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Ixl Dulbecco's phosphate buffered saline (D-PBS). The range of concen- 
trations varied between 0.2 o.g/ml (radioactive molecule alone) to 100 ~g/ 
ml.  Buffers and the type of microtiter plates used were identical with 
those used for adhesion assays. The plates were left for 1 h at room tem- 
perature, whereupon supernatants were discarded and the plates washed 
twice with D-PBS. Finally, bound protein was released with 0.2 M NaOH 
and 1% Triton X-100 (Fluka) in D-PBS and the radioactivity determined 
in a V-counter. By comparing the input radioactivity with bound radioac- 
tivity, the percentage of bound soluble recombinant molecules was calcu- 
lated for each protein concentration and the quantity of bound soluble re- 
combinant molecules per mm  2 was determined. 
Cell Adhesion Assays 
Purified adhesion molecules were directly coated onto microtiter wells 
(Costar, Cambridge, MA) at 10 ixg/ml in 50 ~1 D-PBS for 2 h at room tem- 
perature. The wells were blocked with 20% BSA for 1 h at room tempera- 
ture and washed five times with D-PBS. 50 Ixl of RPMI 1640 medium sup- 
plemented with 0.5%  FCS and 20 mM Hepes, hereafter referred to as 
RPMI-Hepes medium, were added to the wells. Antibodies and peptides 
were diluted in RPMI-Hepes medium at triple concentrations. The ceils 
were released from the culture  flask,  washed three times with RPMI- 
Hepes medium, saturated with Na51CrO4 (Amersham, UK) (35  ~Ci/5  × 
106 cells) for 30 min at 37°C, washed twice with RPMf-Hepes medium and 
adjusted to 106 cells/ml. 100 Ixl of the cell suspension were added to appro- 
priately pretreated wells and incubated for 30 min on ice to allow antibod- 
ies to bind. After this the plates were rapidly warmed to 37°C and incu- 
bated for 45 min on a gyratory platform (Kiihner, Basel, Switzerland) at 
50 rpm. Unbound cells were removed by washing three times with D-PBS 
containing 1%  BSA prewarmed at 37°C.  The level of radioactivity re- 
tained in each well was released by short treatment of the wells with 1% 
Triton X-100 in RPMI-Hepes medium and ~/-ray emissions of well con- 
tents were determined. The addition of 0.5% FCS did not alter the results, 
since adhesion assays performed without addition of protein to the RPMI- 
Hepes solution, 0.5% BSA or 0.5% normal mouse serum showed similar 
blocking effects with anti-av antagonists. Also, adhesion assays to CD31- 
3D was repeated with two further independently cloned CD31-3D mole- 
cules to exclude the possibility that somatic mutations were introduced to 
the CD31cDNA while integrated in the myeloma genome. 
The quantification of LAK cell binding to the cultured endothelioma 
cell line eEnd.2 was performed as described (56).  Briefly, 3  ×  104 endo- 
thelioma cells were seeded into 96-well microtiter plates (Costar) and cul- 
tured for 24 h. After washing the cells twice with RPMI-Hepes medium, 
antibodies and/or additional reagents were added. LAK cells were added, 
incubated for 30 rain on ice and then incubated at 15°C for 45 min and an- 
alyzed as described above. 
Data are expressed as % binding relative to the control group. 10651Cr- 
labeled  LAK  cells  represented  3.3-8.5  ×  105  cpm,  106  51Cr-labeled 
FTF1.26 cells represented ~i.1 ×  105 -  1.2 ×  106 cpm. Coating of wells by 
10 ixg/ml CD31 generally lead to the binding of 4-20% adhesion according 
to the batch of LAK cells used. Coating of 120 Dxg/ml  doubled the number 
of bound cells. In both cases, binding could be inhibited by anti-~tv133 anti- 
bodies. When assayed on endothelial cells, 20-30% of all added LAK cells 
bound. 
Affinity Isolation of CD31 Ligand 
E.End.2 or LAK cells were surface labeled for 45 min with 125I (Amer- 
sham) followed by thorough washes with PBS. The following steps were 
all performed at 4°C. The pellet was lysed in 30 mM Octyl-13-D-glucopy- 
ranoside (Fluka), 50 mM Tris-HCl, pH 7.4, 150 mM NaCI, 1 mM MnClz, 
1 mg/ml Ovalbumin, 1 mM PMSF, 10 I~g/ml leupeptin and 2.3 TIU/ml of 
Aprotinin (all Sigma Chem. Corp., St. Louis, MO) for 10 min. The lysate 
was then precleared from nonspecifically binding material with ~50 ~1 of 
packed Sepharose (Pharmacia). The precleared lysate was then aliquoted 
and incubated with ~30 Izl preformed affinity matrices. The affinity matri- 
ces were prepared by incubating 4 mg of rat anti-mouse cK mAb 187.1 
(ATCC)  per ml CNBr-activated Sepharose beads overnight in Borate- 
buffered saline, pH 8.5. After removal of unbound antibodies, the beads 
were incubated with 20 ixg of either CD31-3D or CD4-anti CD3 Janusin, 
washed and resuspended in the appropriate buffer. After incubating the 
labeled cell lysates with  the  affinity matrices for 4  h,  the beads  were 
washed five times with Tris-buffered saline (TBS) pH 8.5, 0.05% Triton 
X-100, 1 mM MnC12 and twice with a washing buffer lacking MnC12. Elu- 
tion was done twice with 40 ~13 mM EDTA in 50 mM sodium acetate pH 
5.2, 0.05% Triton X-100. Eluted proteins were separated by SDS-PAGE 
under nonreducing and reducing conditions and detected by fluorography 
using Kodak X-OMAT X-ray films or a Phosphorfmager (Molecular Dy- 
namics,  Sunnyvale,  CA)  using  the ImageQuant  TM  software (Microsoft 
Corp. Redmond, WA). For blocking, the precipitations were performed in 
the presence of the anti-avl33 antibody, (dilution: 1:100), anti-[33 antibody 
(30 izg/ml), and anti-131 antibody (30 I~g/ml). 
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Figure 1.  Production of soluble recombinant adhesion molecules. 
(A)  The  molecules  were  produced  in  myeloma  cells,  purified 
from  supernatants  by  affinity  columns,  and  analyzed  on  SDS- 
PAGE  under  nonreducing  conditions  after  staining  with  Coo- 
massie blue. CD31  Ig-domains 1-3 linked to the constant region 
of the K light-chain, CD31-3D (3D); CD31 Ig-domains 1--6 linked 
to  cK,  CD31-6D  (6D);  CD31  Ig-domains  1-6  lacking  domain  2 
linked  to  CK, CD31-6DA2  (6Dr2);  ICAM-1  Ig-domains  1-2-CK, 
ICAM-1  (ICAM);  and  VCAM-1  Ig-domains  1-2-cK,  VCAM-1 
(VCAM).  Molecular  mass  markers  are  indicated  (in  kD).  (B) 
Schematic representation of the truncated recombinant adhesion 
molecules. Open circles represent immunoglobulin-like domains. 
Putatively  conserved  cysteines  forming  intradomain  disulphur 
bridges are represented by a  double s. The enumeration  of do- 
mains starts at the NH2 terminus, the constant domain of the IgK- 
light chain is represented by CK. The bold circles highlight the sec- 
ond Ig domain of CD31 as putative heterophilic-binding site. 
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Recombinant, Soluble Adhesion Molecules 
We  generated  soluble,  recombinant  forms  of truncated 
mouse CD31, ICAM-1, and VCAM-1. To obtain various 
CD31 isoforms, the first three Ig-domains, all six domains, 
or an isoform lacking domain 2 were fused to the c Kappa- 
domain (CK) of the mouse Ig light chain (CD31-3D, -6D, 
and -6DA2, respectively). The RNA for CD3I-6DA2 was 
identified as a naturally occurring splice product found in 
many different endothelial and hematopoietic cell lines of 
mouse origin. The splice product gives rise to an in-frame 
RNA species and protein (unpublished observation). The 
ICAM-1 and VCAM-1 fusion proteins contained the first 
two Ig-domains which included the integrin-binding sites 
(54,  69).  All  molecules  were  constitutively  secreted  by 
transfected J558L myeloma ceils and were affinity purified 
with anti-cK columns (Fig. 1). The observed differences in 
apparent molecular weight between ICAM-1 and VCAM-1 
are not readily explicable but could represent glycosylation 
differences. Indeed, the two first Ig-domains of VCAM-1 
contain  no  glycosylation  sites  whereas  ICAM-1  bears 
three potential N-glycosylation sites (5, 31). 
heterophilic way. In contrast, the pro-T--cell line FTF1.26 
moderately adhered to the 3D form but strongly bound to 
the full-length CD31 molecule. In the presence of EDTA, 
residual binding of the cells to the 3D form was lost but 
binding to the 6D molecule persisted (Fig. 3 b). These re- 
suits pointed out that FTF1.26 cells may preferentially ad- 
here to CD31 in a homophilic way. Similar to LAK cells, 
FIT1.26 cells did not bind to CD31-6DA2, confirming that 
cation-independent interaction between two CD31 mole- 
cules requires six Ig domains (24).  Taken together, these 
data  show that truncated,  recombinant CD31  molecules 
can function as  cation-independent  or cation-dependent 
ligands, depending on the cell line and the type of recom- 
binant CD31 molecule used. 
It has been shown that CD31 binds to GAGs via a con- 
sensus heparin-binding motif in the second Ig-like domain 
(22).  In fact, when used as primary reagents and then de- 
veloped  with  an  anti-cK  antibody,  the  CD31-3D  and 
CD31-6D, but not the CD31-6DA2, constructs were able 
to stain heparin-containing mast cells on frozen sections of 
a 
100.  Cation-dependent and Cation-independent Adhesion 
Mediated by CD31  "~ 
o  80. 
0 
The truncated forms of CD31 were directly coated onto 
microtiter wells and used for cell-adhesion experiments. A  ~  60. 
solution of 10 ~g/ml of recombinant soluble CAMs were 
incubated in microtiter wells and the amount bound to the  m  40. 
plastic  surface  was  determined  (Fig.  2).  The  adhesive 
properties  of lymphokine-activated killer  (LAK) cells,  a  20. 
heterogeneous cell line derived from IL-2-activated sple- 
nocytes (29), were studied. These ceils adhered consider-  o 
ably to  the  3D-,  moderately to  the  6D-  and  not to  the 
6DA2-form  of  CD31  although  double  the  amount  of  b 
CD31-6D  than  CD31-3D molecules were  ligated  to the 
microtiter well (Figs. 2  and 3 a). The binding to the 3D  200. 
form was exquisitely dependent on divalent cations since  180- 
adhesion was inhibited with 5 mM EDTA. The cation de-  ~  160. 
pendence  and the  lack of adhesion to  CD31-6DA2 sug- 
gested that LAK ceils might interact with CD31-3D in a 
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Figure 2.  Binding of soluble recombinant adhesion molecules to 
microtiter well surface. The number of molecules bound on the 
surface of the microtiter well was determined as described in the 
Materials and Methods section. The amount of CD31-3D, CD31- 
6D, CD31-6DA2, VCAM-1, and ICAM-1 bound to the plates is 
expressed as pmol per mm  2. 
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Figure 3.  Leukocyte binding: cation-dependent  and cation-inde- 
pendent  CD31 interactions. Cells were allowed to bind to plates 
coated  with  recombinant  molecules.  (a)  LAK cell binding  to 
CD4, CD31-3D, CD31-6D, and CD31-6DA2 soluble molecules in 
the presence of 1 mM Ca  ++ and 1 mM Mg  +÷ (open bars) or in the 
presence of 5 mM EDTA (hatched bars). (b) FTF1.26 cell bind- 
ing to CD4, CD31-3D, CD31-6D, and CD31-6DA2 molecules in 
the presence of 1 mM Ca  ++ and 1 mM Mg  +÷ (open bars) or in the 
presence of 5 mM EDTA (hatched bars). Data are expressed as 
mean  percentage  of binding  -+  SE of mean  of three  replicate 
wells. 100% is equivalent to 1,400 cpm in a and 11,500 in b, two 
independent experiments with similar results were done. 
The Journal of Cell Biology,  Volume 130, 1995  454 Figure 4.  Histochemical staining of C.B-17 SCID mouse thymus sections. Frozen sections of the thymus (6 ~m) were incubated with sol- 
uble recombinant molecules and developed with alkaline phosphatase-coupled secondary antibodies. (a) Labeling of SCID thymus with 
10 ~g/ml CD31-3D. (b) Labeling of SCID thymus with 10 Ixg/ml  CD31-3D in the presence of 100 ixg/ml Heparin. (c) Control labeling of 
SCID thymus with CD4-anti CD3 Janusin. (d) Labeling with rat-anti-mouse heparan sulfate proteoglycan mAb 1948. Original magnifi- 
cation: 1,000; Bar, 8.5 ~m. 
spleen and thymus, and this was inhibitable by an excess of 
heparin  (Fig.  4  and  data  not shown).  An  mAb  directed 
against  heparan  sulfate proteoglycan leads  to  a  staining 
comparable to CD31-3D  (Fig. 4 d). However, in the cell 
adhesion  assays  cation-dependent binding  to  CD31  was 
not inhibitable by the same heparin preparation (Fig. 5). 
Thus, the CD31-3D and CD31-6D constructs bind GAGs 
by the second Ig-like domain and  an additional, yet un- 
identified, heparin-independent ligand. 
Leukocyte-Endothelial Adhesion: 
Inhibition of CD31-mediated Leukocyte Binding 
by Anti-avfl3 Antagonists 
The  heparin-independent  interaction  of LAK cells with 
CD31-3D was further investigated. Binding of LAK cells 
was inhibited by saturating concentrations of a polyclonal 
antiserum raised against CD31 (Fig. 6). Furthermore, a se- 
ries  of antibodies  directed  against  cell  surface  adhesion 
molecules were screened for inhibitory activities. Surpris- 
ingly, saturating concentrations of a polyclonal rabbit anti- 
serum raised against native Otv[33 integrin reduced binding 
of LAK cells to CD31-3D to background levels (Fig. 6). 
Two blocking monoclonal antibodies (mAbs) reactive with 
the cell surface et  v integrin chain (H9.2B8 [46], and RMV-7 
[72]) and a [33 integrin chain specific mAb were also able to 
inhibit  binding  of  LAK  cells  to  CD31-3D.  In  contrast, 
blocking  antibodies  against  aL-  or  [31  integrin  (43,  63) 
chains did not inhibit CD31-3D-LAK cell binding (Fig. 6). 
To exclude artefactual binding of LAK cells, adhesion 
assays were performed with the recombinant cell-cell ad- 
hesion molecules ICAM-1 and VCAM-1. LAK cell bind- 
ing to ICAM-1 was inhibited by antibodies against etL in- 
tegrin (FD441.8) but not by the anti-av antibody H9.2B8 
(Fig. 7). Binding to VCAM-1 was inhibited by antibodies 
against ~4 (PS/2) (48) integrin, but not by anti-et  v (Fig. 7). 
In contrast, binding of LAK cells to CD31-3D was inhib- 
ited by both anti-cry mAbs H9.2B8 and RMV-7 (Fig. 7 and 
not shown).  This showed that  the  inhibition exerted by 
H9.2B8 and RMV-7 to CD31-3D was specific. It is well es- 
tablished that RGD specific integrins can be inhibited by 
peptides containing the RGD motif. The peptide RGDS 
inhibited binding to CD31-3D in a dose-dependent man- 
ner and reached maximal blocking activity at 5 ~g/ml. A 
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Figure 5.  Leukocyte binding to CD31 is not inhibitable by Hep- 
arin. LAK cells were allowed to bind to CD31-3D in the presence 
of graded concentrations of Heparin. Data are expressed as mean 
percentage of binding  ±  SE of mean of three  replicate  wells. 
100% binding is equivalent to 1,500 cpm, two independent exper- 
iments with similar results were done. 
control peptide of the same size and similar charge had no 
effect at up to 50 ixg/ml (Fig. 8). Since the CD31 molecule 
does not contain  RGD  sequences,  we conclude that  the 
binding epitope on the O~v~  3 molecule making contact with 
CD31 is either influenced by or identical with the RGD- 
binding  site.  Since  both  adhesion  molecules,  etv133 and 
CD31, are strongly expressed by subsets of leukocytes (30, 
46, 58, 71, 72) and endothelial cells (14, 18, 28), we tested 
whether Otv133 interaction with CD31 is involved in leuko- 
cyte-endothelial adhesion. To this end, LAK cells were al- 
lowed to bind to monolayers of endothelial cells. Saturat- 
ing  concentrations  of  antibodies  directed  against  CD31 
inhibited  cell  binding  by  ~30%,  those  against  av133 by 
,--~20% (Fig. 9). The high amount of anti-CD31 antibodies 
used for blocking did not allow CD31 cross-linking which 
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Figure 6.  Binding of LAK cells to CD31 is dependent on integrin 
Ctvl33. LAK cell binding to CD31-3D without antibody (co 1) or in 
the presence of 50 I~g/ml blocking antibodies.  The monoclonal 
antibodies were anti-cry integrin H9.2B8 (av 1),  anti-av integrin 
RMV-7  (c~  v 2),  anti-ct L integrin  FD441.8  (aL),  anti-131 integrin 
9EG7 (fit) and anti-133 integrin Hm133 (/33). The polyclonal rabbit 
antibodies were used at a dilution of 1:10. Preimmune serum (co 
2),  antiserum directed against txv133 integrin (av/33) or antiserum 
raised  against  CD31-6D (CD31). Data are expressed  as mean 
percentage  of binding  +_  SE of mean of three  replicate wells. 
100%  binding is equivalent to 1,600 cpm, three independent ex- 
periments with similar results were done. 
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Figure 7.  Inhibition by anti-ct  v is specific.  LAK cell  binding to 
CD31-3D, VCAM-1, and ICAM-1 without antibody (co) or in 
the presence of 50 txg/ml blocking antibodies.  The monoclonal 
antibodies were anti-ct  v integrin H9.2B8 (avl),  anti-a4 integrin 
PS/2 (a4), and aL integrin FD441.8 (aL). Data are expressed as 
mean percentage of binding  -4-  SE of mean of three  replicate 
wells.  100%  binding is equivalent to 1,400 cpm, three indepen- 
dent experiments with similar results were done. 
would  result  in  integrin  activation,  and  thus  enhanced 
binding, as described previously (56, 73). To prove that the 
interaction of eCv~  3 with CD31 was involved, combinations 
of both Abs were applied and no additive blocking effect 
was observed. This shows that av133 integrin can recognize 
CD31 in its native conformation state in the membrane of 
another cell. 
Precipitation of avfl3 by CD31 
Direct evidence for binding of CD31 to ~tv133 integrin was 
obtained by immunoprecipitation experiments using CD31- 
3D as an affinity matrix. Elution with EDTA revealed two 
major proteins with apparent molecular masses of 145 kD 
and 85 kD on SDS-PAGE under nonreducing conditions. 
The  apparent  sizes  of the  precipitated  molecules  corre- 
sponded to the published molecular weights of the cry and 
133 integrin chains (49). A  control construct, the CD4-anti- 
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Figure 8.  Binding of LAK cells  to CD31 is inhibited  by RGD 
peptides.  LAK cell  binding  to  CD31-3D  in  the  presence  of 
graded  concentrations  of peptides.  The  peptides  were  TKPR 
(open bars) and RGDS (hatched bars). Data are expressed  as 
mean percentage  of binding  _+  SE of mean of three  replicate 
wells. 100% binding is equivalent to 1,500 cpm, four independent 
experiments with similar results were done. 
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Figure 9.  Binding of LAK cells to endothelioma cells is partially 
mediated by ctv133-CD31 interactions. LAK cell binding to mono- 
layers of the endothelioma cell line eEnd.2 in the presence of an- 
tibodies  directed  against  Ctv133 (a~/33), CD31  (CD31),  combina- 
tions of both (CD31  + av/33) or control preimmune serum (co 2) 
at dilutions of 1:30. Data are expressed as mean percentage of 
binding  +- SE of mean of three replicate wells.  100% binding is 
equivalent  to 23,000  cpm, three  independent  experiments with 
similar results were done. 
CD3-cK Janusin  chimaeric molecule  (74), was not able to 
precipitate this protein. Identity of the molecules detected, 
was documented by precipitations done in the presence of 
anti-e~v[33 polyclonal antibodies, anti-133, and anti-131 mono- 
clonal  antibodies  (Fig.  10 A).  Alternatively,  the  material 
was precipitated by the CD31-3D affinity matrix, eluted by 
EDTA  treatment  and  reprecipitated  by  an  antibody  di- 
rected  against  the  etv[33 integrin  (Fig.  10 B).  Upon  reduc- 
tion, the Ctv molecule precipitated by CD31-3D migrated at 
125 kD. The apparent molecular weight of the ~3 chain in- 
creased upon reduction  to 100 kD (34)  (Fig.  10 B). More- 
over,  an  additional  protein  with  diffuse  appearance  was 
precipitated  with  CD31-3D  from  endothelial  cell  lysates 
(Fig. 10 A). Recognition of this molecule by CD31-3D was 
not  perturbed  by antibodies  to etv~3 and  could  represent 
an  additional  cation-dependent,  heterophilic  ligand  for 
CD31. 
Discussion 
Taken  collectively,  we  conclude  that  CD31  can  directly 
bind  to  the  Otvl33 integrin,  and  that  the  etv133 integrin  and 
CD31  constitute  a  heterophilic  receptor  ligand  pair.  This 
adds a third Ig-SF-integrin pair to the previously described 
ICAM/132 integrins and VCAM-1, MadCAM-1/et4 integrin 
pairs. 
Cells can undergo cation-dependent,  heterophilic or cat- 
ion-independent,  homophilic adhesion mediated by CD31 
(19,  22,  50).  We  showed  that FTF1.26  cells preferentially 
undergo  cation-independent  CD31  interactions  whereas 
LAK  cells  bind  via  heterophilic  CD31-etv133  contacts. 
These  binding  differences  are  not  merely exclusive  since 
LAK cell binding in the presence of EDTA  to the CD31- 
6D  molecule  is  not  completely  abrogated  (Fig.  3  a)  and 
FTF1.26  cell binding to the CD31-3D molecule is blocked 
by EDTA  (Fig.  3  b). Thus, both mechanisms can operate 
in parallel. However, cation-independent,  homophilic, and 
cation-dependent,  heterophilic  interactions  may offer the 
possibility for regulation of the adhesion type. It has been 
shown that a  regulatory domain of CD31 is located in the 
cytoplasmic  tail.  Experimental  truncation  of this  domain 
leads to CD31 that can only interact in a homophilic man- 
ner  (19).  Indeed,  such regulations  of CD31  function  may 
Figure 10.  CD31-3D specifically precipitates OLv~  3 integrin. (A) Immunoprecipitations with 1251 surface-labeled endothelial cell lysates. 
The affinity matrices were prepared with CD4-anti-CD3-cK Janusin as control (CD4) and CD31-3D (CD31) used as such or in the pres- 
ence of anti-c~v133  antibodies (av/33), anti-133 antibodies (133) or anti-131 antibodies (/31) and separated under nonreducing (NR) and reduc- 
ing conditions  (R).  (B) Immunoprecipitations with  125I  surface-labeled LAK cell lysates. The affinity matrices were prepared with 
CD31-3D (CD31) and the control CD4-anti CD3-cK Janusin (CD4). LAK cell lysate was immunoprecipitated with anti-etv133  antibody. 
The material eluted from the CD31 and CD4 affinity matrices was further immunoprecipitated with anti-c~vl33 antibody and analyzed 
under reducing conditions (R). The proteins were separated on 8% polyacrylamide gels. Molecular mass markers are indicated (in kD). 
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cytoplasmic region comprises seven exons and several al- 
ternatively spliced mRNAs have been reported, leading to 
CD31 variants showing homophilic or heterophilic binding 
(6,  39).  Our  finding of an  integrin being  a  heterophilic 
ligand for CD31 now offers a possibility for rapid changes 
of CD31-mediated  adhesion.  Integrins  can  switch  from 
low to high affinity states by cell activation, addition of 
Mn +÷ leads to a fully activated high affinity state (34). In- 
deed, addition of 0.5 mM Mn  ÷+ to the medium increases 
the binding of LAK cells to CD31-3D approximately six- 
fold (data not shown). Since CD31 interacts with avl33 inte- 
grin, regulation of the adhesive capacity of CD31 depends 
on the regulation of the integrin. 
It has been recognized that in order for leukocytes to ar- 
rest and leave the bloodstream during normal recircula- 
tion and inflammation, it would require a multitude of ad- 
hesive interactions with the  endothelium. These include 
rolling, mediated by selectins, tight adhesion to the endo- 
thelium conferred by integrins and subsequent transendo- 
thelial migration, partially due to integrins(for reviews see 
1, 35, 68). Our results point to a role of etv133 in this adhe- 
sion cascade. Integrin c~133 is expressed by LAK cells and 
endothelial cells (Fig. 10, A  and B). Furthermore, the ad- 
hesion of LAK cells to endothelial monolayers was inhib- 
itable  with  antibodies  directed  to  Otv[33 integrin  and  to 
native CD31 (Fig. 9). Since the blocking effect of the anti- 
bodies was not additive, we conclude that indeed avl33 and 
CD31 form an adhesion molecule pair involved in the ad- 
hesion of leukocytes to endothelium. Formerly, integrin 
av~ 3 has been shown to be a major receptor mediating mi- 
gration  of cells  on ECM  substrates  (41,  42).  CD31  ex- 
pressed by endothelial cells might represent a  surrogate 
substrate for lymphocyte migration on the endothelial cell 
surface  and  intercellular  junctions,  where  immobilized 
ECM components are mostly absent. 
The transendothelial migration of monocytes has been 
shown  to  be  crucially dependent  on  CD31  (51).  It  was 
however not possible to discriminate whether the  CD31 
molecules mediated  this  process by homophilic interac- 
tions or in a heterophilic manner. Two circumstances point 
to heterophilic interactions, first, the transendothelial mi- 
gration of monocytes was inhibited by an mAb directed 
against  domain  2  and  second,  the  soluble  recombinant 
CD31 molecule used for blocking, lacked half of domain 6, 
a domain essential for homophilic binding (24, 51). How- 
ever, transendothelial migration was blocked irrespective 
of whether the monocytes or the  endothelial cells were 
preincubated alone with anti-CD31 antibodies. This could 
be due to CD31  and tXvl3S integrin expression by mono- 
cytes (64) as well as endothelial cells (14). Thus both en- 
dothelial and monocyte av133 integrin may use CD31 as a 
ligand. In contrast to monocytes, lymphocytes which mi- 
grated  through  endothelial  cell  layers  did  not  express 
CD31. This would allow only heterophilic interactions if 
CD31 was involved in the migration of these cells (8). 
VLA-4 (a4131) is another integrin involved in leukocyte 
transendothelial migration. It also recognizes both an IgSF 
molecule, VCAM-1, and molecules of the ECM, the IIICS 
domain of fibronectin (2, 32, 53). It appears, that the IgSF 
members  VCAM-1  and  CD31  are  the  migration-sub- 
strates for leukocyte integrins ~41~1 and Otv~3, respectively, 
and that migration within the ECM continues to depend 
on these integrins. This minimizes complicated regulatory 
switches from cell-dependent to ECM-dependent migra- 
tion. In addition, the two integrins have further functional 
aspects in common. Cross-linking of both Ota[~  1 and Otv~ 3 by 
their ligands induces the expression of metalloproteinases 
(59, 65). These enzymes are crucial for the invasive pro- 
cess, i.e., for the digestion of the basement membrane, a 
prerequisite for the entry of cells into tissue. It remains to 
be investigated whether the interaction of Otv133  with CD31 
may induce the release of proteases. 
Heterophilic ligands for CD31  have been identified as 
cell surface glycosaminoglycans (GAGs)  (22).  Although 
our  CD31  constructs  recognized  heparan  sulfate  pro- 
teoglycan-binding epitopes,  the  cell  lines  did  not  show 
GAG-dependent adhesion to CD31 (Figs. 4 and 5). Here 
we studied the adhesion of activated leukocytes whereas 
in other studies L-cell aggregation assays were used (22, 
50). It is conceivable that these leukocytes do not express 
the GAGs binding to CD31. The additional molecule de- 
tected by precipitation of endothelial cell lysates with the 
CD31-3D affinity matrix, might represent the second c~v[33- 
independent ligand (Fig. 10 A). This molecule was not de- 
tected in precipitations done with LAK cell lysates (Fig. 10 
B). Thus it seems that CD31 has two heterophilic cellular 
ligands,  GAGs and etv[33 integrin.  Since etvl33 dependent 
binding of LAK cells to CD31  occurs in the presence of 
heparin,  it  is  likely  that  CD31  uses  different  binding 
epitopes, both residing within the second Ig-like domain 
(Fig. 3 a). 
The etv integrins have been described as cell adhesion 
molecules for the ECM (82). The RGD sequence is widely 
distributed within the molecules of the ECM and is readily 
used as attachment site for many different integrins (for 
reviews see  60,  82).  Yet  CD31  is  not  a  member of the 
ECM and does not contain an RGD  sequence (52,  81). 
However, et  v integrins can bind to non-RGD sequences as 
has been shown for HIV Tat Protein, and fragments of os- 
teopontin  (77,  78).  Although  this  osteopontin  fragment 
did  not  contain  an  RGD  sequence,  its  interaction with 
tXv[33 was inhibitable by RGD peptides. This effect is simi- 
lar to our finding with ctv133  binding to CD31. This confirms 
that  alternative  recognition  sequences  for  Ctv  integrins 
other than  RGD  do  exist  as  reported for c~5131 integrin 
(40). These may be specific for subclasses of RGD-binding 
integrins, i.e., be specific for Otv~ 3. 
Similarly  to  leukocytes,  metastasizing  malignant  cells 
are  transported by the blood to distant  tissues  (70).  On 
melanoma cells, increased expression of Otv[~  3 is positively 
correlated with increased malignancy (3, 26, 27, 45). It has 
been shown that metastatic cells have to adhere to the vas- 
cular endothelium before they can reach the subendothe- 
lial matrix, containing the ECM ligands for Otv~ 3 (79). It is 
conceivable that CD31 plays a role in the tumor cell adhe- 
sion to endothelium, an important step in the metastatic 
process. 
Angiogenesis has been shown to depend on the adhe- 
sive interactions of vascular endothelial cells (for reviews 
see 9, 47). Angiogenic vascular endothelium showed an in- 
crease in expression of tXvl33 integrin (10). Blocking of Ctv133 
by antagonists disrupted the new formation of blood ves- 
sels and rendered the endothelial cells apoptotic (11). Fur- 
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anti-CD31 antibodies failed to form normal cell--cell con- 
tacts (4, 21). Although CD31 can mediate cell-cell contact 
in a homophilic manner and etvl33 may confer endothelial 
ECM contacts, the novel O~v133-CD31 ligand pair might be 
involved in angiogenesis. 
In view of the possible implications, blocking of 0~133- 
CD31 dependent adhesion may offer important targets for 
therapeutic interventions in  the  treatment of inflamma- 
tion, angiogenesis, and metastasis formation. 
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